Print

BioXell S.p.A. And Lay Line Genomics S.p.A. Announce License Agreement For Anti-TrkA Antibody Against Pain  
2/13/2006 2:12:20 PM

BioXell S.p.A. and Lay Line Genomics S.p.A. (LLG) today announced an exclusive, worldwide license agreement for the development of MNAC13, a novel humanized monoclonal antibody that binds to TrkA receptors, blocking the action of Nerve Growth Factor (NGF), a key mediator of pain. According to the agreement, BioXell will take MNAC13 through development and potential commercialisation, in exchange for an undisclosed upfront payment, milestones and royalties to LLG.
//-->